Mumbai, June 22, 2017: Alembic Pharmaceuticals has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Candesartan Cilexetil Tablets, 32 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Atacand Tablets, 32 mg of AstraZeneca Pharmaceuticals LP. Candesartan Cilexetil Tablets are indicated for treatment of hypertension in adults and children and treatment of heart failure (NYHA class II-IV).
Candesartan Cilexetil Tablets, 32mg have an estimated market size of USD 27 million for twelve months ending December 2016, according to IMS.
United News of India
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…